AVALYN PHARMACEUTICALS (AVLN) Stock Price, News & Analysis
Company Description
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for serious, rare respiratory diseases. The company focuses on pulmonary fibrosis and other interstitial lung diseases, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Its common stock is listed on the Nasdaq Global Select Market under the ticker symbol AVLN.
Avalyn's pipeline is built around inhaled formulations of established antifibrotic drug classes. Its lead programs include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. The company is developing these candidates for pulmonary fibrosis indications where treatment is directed at lung tissue affected by progressive scarring and impaired respiratory function.
The company's development model centers on targeted delivery of antifibrotic therapy through inhalation. Avalyn's research activities include clinical studies, quantitative lung imaging, patient-reported quality-of-life measures, supportive care research, and work on how patients and caregivers experience inhaled treatment. Company news has also described the use of high-resolution computed tomography imaging in AP01 research and the evaluation of AP01 delivery and supportive care experiences in pulmonary fibrosis.
Avalyn reports one operating and reportable segment: the business of developing and commercializing targeted therapies for rare lung diseases. As a clinical-stage biopharmaceutical company, its operating activities are concentrated on drug development, clinical program execution, product development, medical research, and preparations associated with potential commercialization of respiratory therapies.
Avalyn became a Nasdaq-listed public company following the closing of its initial public offering of common stock. Its public-company profile includes capital-structure matters related to its listed shares, governance updates related to its board and leadership structure, and operating updates tied to its AP01 and AP02 programs.
Stock Performance
AVALYN PHARMACEUTICALS (AVLN) stock last traded at $29.70. Over the past 12 months, the stock has gained 0.8%. At a market capitalization of $1.5B, AVLN is classified as a small-cap stock with approximately 44.3M shares outstanding.
AVLN Rankings
Latest News
AVALYN PHARMACEUTICALS has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, acquisition, IPO, offering, management. View all AVLN news →
SEC Filings
AVALYN PHARMACEUTICALS has filed 5 recent SEC filings, including 3 Form 8-K, 1 Form 10-Q, 1 Form SCHEDULE 13D. The most recent filing was submitted on July 1, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AVLN SEC filings →
Insider Radar
Insider buying activity at AVALYN PHARMACEUTICALS over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
AP03 Phase 1 start planned
AURA AP02 topline data
Topline 12-month results
AVALYN PHARMACEUTICALS has 3 upcoming scheduled events. The next event, "AP03 Phase 1 start planned", is scheduled for December 31, 2026 (in 180 days). Investors can track these dates to stay informed about potential catalysts that may affect the AVLN stock price.
Short Interest History
Short interest in AVALYN PHARMACEUTICALS (AVLN) currently stands at 1.3 million shares, up 46.1% from the previous reporting period, representing 3.1% of the float. Over the past 12 months, short interest has increased by 132.8%. This relatively low short interest suggests limited bearish sentiment. The 5.5 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for AVALYN PHARMACEUTICALS (AVLN) currently stands at 5.5 days, up 71.7% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 309.6% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.4 to 5.5 days.
AVLN Company Profile & Sector Positioning
AVALYN PHARMACEUTICALS (AVLN) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,279 among all tracked companies.